Intact Investment Management Inc. increased its position in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 38.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 261,300 shares of the company's stock after buying an additional 72,300 shares during the period. Intact Investment Management Inc. owned about 0.07% of Bausch Health Companies worth $2,112,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Tobam increased its position in shares of Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after purchasing an additional 1,422 shares during the last quarter. DGS Capital Management LLC bought a new stake in shares of Bausch Health Companies in the 4th quarter worth about $143,000. Kendall Capital Management increased its position in shares of Bausch Health Companies by 43.4% in the 4th quarter. Kendall Capital Management now owns 17,995 shares of the company's stock worth $145,000 after purchasing an additional 5,445 shares during the last quarter. Principal Securities Inc. increased its position in shares of Bausch Health Companies by 39.7% in the 4th quarter. Principal Securities Inc. now owns 19,220 shares of the company's stock worth $155,000 after purchasing an additional 5,464 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Bausch Health Companies in the 4th quarter worth about $180,000. Institutional investors own 78.65% of the company's stock.
Bausch Health Companies Price Performance
Shares of NYSE:BHC traded down $0.02 during trading on Wednesday, reaching $7.00. 1,831,993 shares of the company's stock traded hands, compared to its average volume of 2,701,199. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $11.46. The company has a 50 day moving average of $7.18 and a 200-day moving average of $7.68. The stock has a market capitalization of $2.57 billion, a P/E ratio of -58.29, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59.
Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The business had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. Equities research analysts predict that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada decreased their price target on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Bausch Health Companies presently has an average rating of "Hold" and an average price target of $7.42.
View Our Latest Stock Report on BHC
About Bausch Health Companies
(
Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
